You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 東陽光藥(1558.HK)反彈逾15%止步7連跌 自研甘精胰島素注射液獲批上市
格隆匯 11-03 15:35
格隆匯11月3日丨此前連續下跌的東陽光藥(1558.HK)觸底反彈,尾盤漲幅擴大至超15%,近日走出7連跌創下歷史新低價,現現3.82港元,總市值34億港元。公司日前宣佈,自主研究及開發的產品甘精胰島素注射液已獲中國國家藥品監督管理局審批完畢並獲准上市。該產品成功獲批上市,有益於拓展集團內分泌及代謝治療領域業務,並進一步豐富了集團的產品組合。此外,公司預計剩餘在研產品將於今年內全部獲批,料兩個新藥將在2023-2024年上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account